Skip to main content

Table 1 Baseline characteristics of treatment courses for axSpA patients initiating a TNFi

From: Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors

Variable All TC
(n=1668 TCs)
All TC with mMASES ≥1 at baseline (n=1117) All TC with mMASES = 0 at baseline (n=551)
Age (years), median (IQR) 42 (33–51) 43 (34–51) 41 (32-51)
Men, n (%) 886 (53.1) 531 (47.5) 355 (64.4)
BMI, median (IQR) 25.3 (22.5–28.6)
n=1408
25.7 (22.8–29.3)
n=932
24.7 (22.3-27.3)
n=476
Disease duration (years), median (IQR) 9 (4–18)
n=1633
9 (4–17)
n=1092
10 (4-19)
n=541
HLA-B27+, n (%) 984 (65.7)
n=1498
617 (61.5)
n=1003
367 (74.1)
n=495
ASAS axial SpA criteria positive, n (%)a 1158 (76.4)
n=1515
764 (76.2)
n=1003
396 (77.2)
n=513
Enthesitis (mMASES >0) at baseline, n (%) 1117 (67.0) 1117 (100) -
mMASES, median (IQR) 2 (0–4) 3 (2–6) -
Elevated CRP, n (%) 987 (60.1)
n=1642
641 (58.4)
n=1098
346 (63.6)
n=544
ASDAS-CRPb, median (IQR) 3.3 (2.6–3.9)
n=1220
3.4 (2.8–4.0)
n=816
3.0 (2.3-3.7)
n=404
BASDAI scorec, median (IQR) 5.7 (4.1–7.0)
n=1337
6.1 (4.7–7.3)
n=889
4.6 (2.9-6.2)
n=448
Ever experienced uveitis, n (%) 258 (16.5)
n=1567
146 (13.9)
n=1054
112 (21.8)
n=513
Ever experienced arthritis, n (%) 963 (57.7) 707 (63.3) 256 (46.5)
Ever experienced dactylitis, n (%) 214 (12.9)
n=1655
168 (15.0)
n=1108
46 (10.3)
n=447
Ever experienced enthesitis at the heel, n (%) 745 (69.5)
n=1072
625 (73.0)
n=856
120 (55.6)
n=216
csDMARD cotherapy, n (%) 392 (23.5) 274 (24.5) 118 (21.4)
TNFi line of therapy, n (%)
 First line 1046 (62.7) 702 (62.9) 346 (62.8)
 Second line 389 (23.3) 261 (23.4) 128 (23.2)
 ≥Third line 233 (14.0) 154 (13.8) 77 (14.0)
  1. aPatients without ASAS axial SpA criteria positive were either ASAS axial SpA criteria negative or unknown due to missing variables
  2. bASDAS disease activity states: inactive (<1.3), low (≥1.3 to <2.1), high (≥2.1 to ≤3.5), very high (>3.5)
  3. cBASDAI scores range from 0 (no disease activity) to 10 (maximum disease activity)
  4. ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, HLA-B27 human leukocyte antigen B27, IQR interquartile range, mMASES modified Maastricht Ankylosing Spondylitis Enthesitis Score (modified to include the plantar fascia), TCs treatment courses, TNFi tumor necrosis factor inhibitor